234 related articles for article (PubMed ID: 10534246)
1. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
Oliveri RL; Annesi G; Zappia M; Civitelli D; Montesanti R; Branca D; Nicoletti G; Spadafora P; Pasqua AA; Cittadella R; Andreoli V; Gambardella A; Aguglia U; Quattrone A
Neurology; 1999 Oct; 53(7):1425-30. PubMed ID: 10534246
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
Zappia M; Annesi G; Nicoletti G; Arabia G; Annesi F; Messina D; Pugliese P; Spadafora P; Tarantino P; Carrideo S; Civitelli D; De Marco EV; Cirò-Candiano IC; Gambardella A; Quattrone A
Arch Neurol; 2005 Apr; 62(4):601-5. PubMed ID: 15824260
[TBL] [Abstract][Full Text] [Related]
3. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.
Lee JY; Cho J; Lee EK; Park SS; Jeon BS
Mov Disord; 2011 Jan; 26(1):73-9. PubMed ID: 20945430
[TBL] [Abstract][Full Text] [Related]
4. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
Strong JA; Dalvi A; Revilla FJ; Sahay A; Samaha FJ; Welge JA; Gong J; Gartner M; Yue X; Yu L
Mov Disord; 2006 May; 21(5):654-9. PubMed ID: 16435402
[TBL] [Abstract][Full Text] [Related]
5. DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
Purcaro C; Vanacore N; Moret F; Di Battista ME; Rubino A; Pierandrei S; Lucarelli M; Meco G; Fattapposta F; Pascale E
Neurosci Lett; 2019 Jan; 690():83-88. PubMed ID: 30316985
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease.
Wang J; Liu ZL; Chen B
Neurosci Lett; 2001 Jul; 308(1):21-4. PubMed ID: 11445276
[TBL] [Abstract][Full Text] [Related]
7. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
Makoff AJ; Graham JM; Arranz MJ; Forsyth J; Li T; Aitchison KJ; Shaikh S; Grünewald RA
Pharmacogenetics; 2000 Feb; 10(1):43-8. PubMed ID: 10739171
[TBL] [Abstract][Full Text] [Related]
8. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.
Comi C; Ferrari M; Marino F; Magistrelli L; Cantello R; Riboldazzi G; Bianchi ML; Bono G; Cosentino M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28125015
[TBL] [Abstract][Full Text] [Related]
10. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks".
Rissling I; Geller F; Bandmann O; Stiasny-Kolster K; Körner Y; Meindorfner C; Krüger HP; Oertel WH; Möller JC
Mov Disord; 2004 Nov; 19(11):1279-84. PubMed ID: 15390060
[TBL] [Abstract][Full Text] [Related]
12. L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
Kaiser R; Hofer A; Grapengiesser A; Gasser T; Kupsch A; Roots I; Brockmöller J
Neurology; 2003 Jun; 60(11):1750-5. PubMed ID: 12796525
[TBL] [Abstract][Full Text] [Related]
13. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
14. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
Rascol O; Nutt JG; Blin O; Goetz CG; Trugman JM; Soubrouillard C; Carter JH; Currie LJ; Fabre N; Thalamas C; Giardina WW; Wright S
Arch Neurol; 2001 Feb; 58(2):249-54. PubMed ID: 11176963
[TBL] [Abstract][Full Text] [Related]
15. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
Foltynie T; Cheeran B; Williams-Gray CH; Edwards MJ; Schneider SA; Weinberger D; Rothwell JC; Barker RA; Bhatia KP
J Neurol Neurosurg Psychiatry; 2009 Feb; 80(2):141-4. PubMed ID: 18977816
[TBL] [Abstract][Full Text] [Related]
16. Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease.
Kwak Y; Bohnen NI; Müller ML; Dayalu P; Burke DT; Seidler RD
Behav Brain Res; 2013 May; 245():128-36. PubMed ID: 23439215
[TBL] [Abstract][Full Text] [Related]
17. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
18. The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease.
Oliveri RL; Annesi G; Zappia M; Civitelli D; De Marco EV; Pasqua AA; Annesi F; Spadafora P; Gambardella A; Nicoletti G; Branca D; Caracciolo M; Aguglia U; Quattrone A
Mov Disord; 2000 Jan; 15(1):127-31. PubMed ID: 10634251
[TBL] [Abstract][Full Text] [Related]
19. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
20. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD.
Zappia M; Annesi G; Quattrone A
Neurology; 2002 Mar; 58(5):837; author reply 837-8. PubMed ID: 11889264
[No Abstract] [Full Text] [Related]
[Next] [New Search]
